USA Financial Formulas’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.56K Sell
61
-993
-94% -$55.4K ﹤0.01% 339
2026
Q2
$57.3K Buy
1,054
+1,040
+7,429% +$50.6K 0.01% 254
2026
Q1
$600 Hold
14
– – ﹤0.01% 372
2025
Q4
$614 Buy
+14
New +$579 ﹤0.01% 349
2025
Q3
– Sell
-6,773
Closed -$299K – 285
2025
Q2
$299K Sell
6,773
-3,157
-32% -$126K 0.05% 101
2025
Q1
$367K Buy
9,930
+8,962
+926% +$319K 0.06% 93
2024
Q4
$32.2K Buy
+968
New +$31.4K 0.01% 246
2024
Q1
– Sell
-2,060
Closed -$49.4K – 342
2023
Q4
$49.4K Buy
2,060
+1,935
+1,548% +$42.1K 0.01% 198
2023
Q3
$2.73K Buy
+125
New +$2.62K ﹤0.01% 308

Other funds holding EXEL

USA Financial Formulas's EXEL Position: Q3 2026 in Review

USA Financial Formulas reduced its Exelixis (EXEL) stake by 94% in Q3 2026, selling an estimated $55.4K and leaving 61 shares worth $3.56K. The position accounts for ﹤0.01% of the portfolio, ranked #339.

USA Financial Formulas first reported a position in EXEL in Q3 2023 and has held it in 9 quarters since. The position peaked at $367K in Q1 2025. 251 funds tracked by Wall St. Rank hold EXEL as of Q3 2026.

  • USA Financial Formulas held 61 shares of Exelixis worth $3.56K as of Q3 2026.
  • USA Financial Formulas sold 993 Exelixis shares in Q3 2026, an estimated $55.4K.
  • Exelixis made up ﹤0.01% of USA Financial Formulas's portfolio in Q3 2026, its #339 holding.
  • USA Financial Formulas first reported a position in Exelixis in Q3 2023 and has held it in 9 quarters since.
  • USA Financial Formulas's Exelixis position peaked at $367K in Q1 2025.
  • 251 funds tracked by Wall St. Rank held Exelixis as of Q3 2026.

Based on USA Financial Formulas's 13F filing for Q3 2026, filed 16 Oct 2026.